Kelly E Moore1, Lindsay Oberleitner, Kathryn M Z Smith, Kathleen Maurer, Sherry A McKee. 1. Department of Psychiatry, Yale University School of Medicine, New Haven, CT (KEM, LO, SAM); Department of Psychiatry, Columbia University, New York, NY (KMZS); Department of Corrections, State of Connecticut, Wethersfield, CT (KM).
Abstract
BACKGROUND: Methadone maintenance treatment (MMT) is underutilized in correctional settings, and those receiving MMT in the community often undergo withdrawal upon incarceration. Federal and state regulations present barriers to providing methadone in correctional facilities. For this investigation, a community provider administered methadone to inmates who had been receiving methadone prior to incarceration. We hypothesized that inmates continued on MMT would have improved behavior during incarceration and post-release. METHODS: This open-label quasi-experimental trial (n = 382) compared MMT continuation throughout incarceration (n = 184) to an administrative control group (ie, forced withdrawal; n = 198) on disciplinary tickets and other program attendance during incarceration. Post-release, re-engagement in community-based MMT and 6-month recidivism outcomes were evaluated. RESULTS: Inmates in the MMT continuation group versus controls were less likely to receive disciplinary tickets (odds ratio [OR] = 0.32) but no more likely to attend other programs while incarcerated. MMT continuation increased engagement with a community MMT provider within 1 day of release (OR = 32.04), and 40.6% of MMT participants re-engaged within the first 30 days (vs 10.1% of controls). Overall, re-engagement in MMT was not associated with recidivism. However, among a subset of inmates who received MMT post-incarceration from the jail MMT provider (n = 69), re-engagement with that provider was associated with reduced risk of arrest, new charges, and re-incarceration compared with those who did not re-engage. CONCLUSIONS: Results support interventions that facilitate continuity of MMT during and after incarceration. Engagement of a community provider is feasible and can improve access to methadone in correctional facilities.
BACKGROUND:Methadone maintenance treatment (MMT) is underutilized in correctional settings, and those receiving MMT in the community often undergo withdrawal upon incarceration. Federal and state regulations present barriers to providing methadone in correctional facilities. For this investigation, a community provider administered methadone to inmates who had been receiving methadone prior to incarceration. We hypothesized that inmates continued on MMT would have improved behavior during incarceration and post-release. METHODS: This open-label quasi-experimental trial (n = 382) compared MMT continuation throughout incarceration (n = 184) to an administrative control group (ie, forced withdrawal; n = 198) on disciplinary tickets and other program attendance during incarceration. Post-release, re-engagement in community-based MMT and 6-month recidivism outcomes were evaluated. RESULTS: Inmates in the MMT continuation group versus controls were less likely to receive disciplinary tickets (odds ratio [OR] = 0.32) but no more likely to attend other programs while incarcerated. MMT continuation increased engagement with a community MMT provider within 1 day of release (OR = 32.04), and 40.6% of MMTparticipants re-engaged within the first 30 days (vs 10.1% of controls). Overall, re-engagement in MMT was not associated with recidivism. However, among a subset of inmates who received MMT post-incarceration from the jail MMT provider (n = 69), re-engagement with that provider was associated with reduced risk of arrest, new charges, and re-incarceration compared with those who did not re-engage. CONCLUSIONS: Results support interventions that facilitate continuity of MMT during and after incarceration. Engagement of a community provider is feasible and can improve access to methadone in correctional facilities.
Authors: Catherine Anne Fullerton; Meelee Kim; Cindy Parks Thomas; D Russell Lyman; Leslie B Montejano; Richard H Dougherty; Allen S Daniels; Sushmita Shoma Ghose; Miriam E Delphin-Rittmon Journal: Psychiatr Serv Date: 2014-02-01 Impact factor: 3.084
Authors: Elizabeth L C Merrall; Azar Kariminia; Ingrid A Binswanger; Michael S Hobbs; Michael Farrell; John Marsden; Sharon J Hutchinson; Sheila M Bird Journal: Addiction Date: 2010-06-23 Impact factor: 6.526
Authors: Kelly E Moore; Walter Roberts; Holly H Reid; Kathryn M Z Smith; Lindsay M S Oberleitner; Sherry A McKee Journal: J Subst Abuse Treat Date: 2018-12-15
Authors: Michael S Gordon; Shannon Gwin Mitchell; Thomas R Blue; Frank J Vocci; Marc J Fishman; Sean M Murphy; Kathy Couvillion; Kelly Maher; Danielle Ryan; Kevin Wenzel; Martha L Danner; Daniel K Jarvis Journal: J Subst Abuse Treat Date: 2020-12-11
Authors: Benjamin A Howell; Lisa Puglisi; Katie Clark; Carmen Albizu-Garcia; Evan Ashkin; Tyler Booth; Lauren Brinkley-Rubinstein; David A Fiellin; Aaron D Fox; Kathleen F Maurer; Hsiu-Ju Lin; Kathryn McCollister; Sean Murphy; Diane S Morse; Shira Shavit; Karen Wang; Tyler Winkelman; Emily A Wang Journal: J Subst Abuse Treat Date: 2021-01-29
Authors: Alissa Haas; Adam Viera; Molly Doernberg; Russell Barbour; Guangyu Tong; Lauretta E Grau; Robert Heimer Journal: Drug Alcohol Depend Date: 2021-07-28 Impact factor: 4.852
Authors: Carolyn Sufrin; Camille T Kramer; Mishka Terplan; Kevin Fiscella; Sarah Olson; Kristin Voegtline; Carl Latkin Journal: JAMA Netw Open Date: 2022-01-04